Since the 1950s, the U.S. Public Health Service (and subsequently the National Institute for Occupational Safety and Health) has conducted a cohort study of more than 4000 uranium miners on the Colorado Plateau (CP) in the southwest United States. These miners were obtaining raw uranium to supply the U.S. nuclear weapons industry from the 1940s to the late 1980s. Initially, researchers administered questionnaires and physical examinations among the miners (both white and American Indian), who are a subset of a much larger group of miners employed during the cold war era. Thousands of measurements were made of radon progeny in hundreds of mines over a period of decades. Since the 1970s, the CP cohort has been followed for mortality and morbidity outcomes and smoking assessment. The unique features of the CP cohort include its high doses, extensive dosimetry, near-complete smoking information, and long follow-up. The cohort has contributed extensively to knowledge of lung cancer risk from radon exposure, including understanding of inverse dose-rate effects, changes in risk with time since exposure, and the form of interaction with smoking. As of the last follow-up in 2005, 75% of the cohort was deceased. Despite the anticipation that lung cancer rates would decline in the late follow-up, published findings suggest that attributable risk of lung cancer continues to be high in the cohort, particularly for miners who smoked little or not at all. The form of interaction of radon dose with smoking appears to remain sub-multiplicative but super-additive. Outcomes other than lung cancer, such as idiopathic pulmonary fibrosis, and some forms of renal disease, have shown associations with radon exposure. With a final wave of follow-up, the CP cohort continues to provide key information to support the development of protective standards to minimise lifetime lung cancer risk from occupational radon exposure.
Occupational and Environmental Medicine. Proceedings of the 25th International Conference on Epidemiology in Occupational Health - EPICOH 2016 - September 4-7, 2016, Barcelona, Spain
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.